Member Info for mulledwine

http://www.investegate.co.uk/Article.aspx?id=201208200700063151K

Outlook The Group expects to be active on an average of 83 sales outlets for H2 2012, an increase of 6% on the 78 achieved in H2 2011. Subject to stable market conditions, this increase in sales outlets will further support reservation levels and underpin the expected growth in total legal completions for 2012 over 2011. Given that the average sales price of private homes, either legally completed to date or sold for 2012 delivery, as at 30 June 2012 stood at £189,300, the Group expects the overall average sales price for 2012 legal completions to be circa 6% greater than that achieved in 2011. The Group has achieved a strong profit margin improvement in the first half of 2012 over H1 2011 and expects that, on the basis of current reservations and subject to stable market conditions, the housing gross margin for the full year will be in the range of 21% to 22%. For full year 2012, overheads as a percentage of total revenue are expected to reduce towards 9% from the 9.8% achieved in 2011. As a result, the Group expects to deliver an operating margin of between 12% and 13% (2011: 10.0%). Return on capital employed for the 2012 full year is expected to approach 7.5% (2011: 5.0%), representing a further significant improvement arising from the Group's growth strategy. Looking ahead to 2013, the Group owns, controls or is currently acquiring a total of around 105 sales outlets which will be operational during 2013 and are expected to contribute circa 90 to the 2013 sales outlet average. The strength of the pipeline of further land acquisition opportunities gives the Group confidence that this average will increase further. With an increasing proportion of legal completions expected from sites acquired since the housing market downturn and with a greater number of active sales outlets, the Group expects that, based on stable market conditions, volumes, average sales price and profit margins will continue to increase in 2013 delivering another strong increase in return on capital employed, which should rise towards 10%. The Group considers that it has the resources and opportunities to continue its strong growth beyond 2013 with the existing financial resources in the Group.

doubling of pre tax profit - not easily done in the current climate.

Commenting on the results, David Ritchie, Chief Executive of Bovis Homes Group PLC said: "The Group has delivered a strong performance during the first half of 2012 with profit before tax doubling against the backdrop of stable, but challenging, market conditions. This increase has been delivered through the compound positive effect of increased volumes, improved average sales price and stronger profit margins. "As a result of a greater number of active sales outlets with an increasing proportion of new, more profitable sites, the Group's profits will, subject to stable market conditions, continue to increase significantly in the second half of 2012, in line with the Group's expectations. "The investments already made in high quality, consented residential land, combined with the strong pipeline of future land opportunities, will support further sales outlet growth into 2013 and beyond. While investing strongly, the Group is controlling capital employed through land bank management and by managing working capital tightly, which will, based on stable market conditions, lead to strongly improving shareholder returns going forward. "With the progressive, sustainable improvement in the Group's profits and the Board's confidence in the Group's growth strategy, the interim dividend has been doubled to 3.0 pence per share."

Current trading and outlook · Strong trading in 2012 to date (33 trading weeks) with a 19% increase in private reservations to 1,253 homes (2011: 1,049) at a sales rate of 0.46 net private reservations per site per week · Sales rates in the last seven weeks at 0.46 net private reservations per site per week, slightly ahead of the comparable prior year period · Cumulative sales achieved to date for 2012 legal completion of 1,968 homes (2011: 1,607) · Sales prices achieved to date marginally ahead of Group expectations · Active sales outlets currently at 82, with an expected average of 83 for 2012 (2011: 73), an increase of 14% · Average sales price for 2012 legal completions expected to be circa 6% greater than 2011, reflecting significant improvements in mix · Housing gross margin expected to be between 21% and 22% for 2012 full year (2011: 20.8%), with an expected operating margin of between 12% and 13% (2011: 10.0%) · Further significant improvement in return on capital employed for the 2012 full year, expected to approach 7.5% (2011: 5.0%)

Operational highlights · Legal completions of 944 homes (H1 2011: 801 homes), an increase of 18% with an average sales price of £164,400 (H1 2011: £163,400) · Average active sales outlets increased by 21% to 82 in H1 2012 from 68 in H1 2011 · Two land sales achieved in H1 2012, delivering a profit of £3.9 million (H1 2011: Nil) · 1,037 consented plots on eight sites added to the land bank during H1 2012, with a further 419 consented plots on two sites added in H2 to date · Contracts in place at 20 August 2012 to acquire another circa 1,200 plots on ten sites, the majority of which are expected to be added to the consented land bank in H2 2012 · Terms agreed in principle to acquire a further 20 sites, representing in excess of 3,000 plots · Consented land bank of 13,620 plots as at 30 June 2012, with potential gross profit of £574 million, calculated using prevailing sales prices and build costs (31 December 2011: 13,723 plots with gross profit potential of £524 million) · 19,829 potential plots of strategic land (31 December 2011: 18,749 potential plots)

http://www.investegate.co.uk/Article.aspx?id=201208200700063147K

A big increase on daily production

Further, an up hole hydrocarbon potential of around 60 meters net thickness, out of which 19 meters is of net oil bearing sands, have been identified in this well and will be taken up for testing in future. This brings to a conclusion a successful seven well development drilling campaign, with six of the seven wells testing oil and producing approximately 550 bopd. The sixth well (KSG-63) of the campaign tested gas and has been kept shut for future gas utilization, as may be commercially viable. The consortium plans to drill six more development wells under the Phase III Extension programme after receiving necessary approvals. GeoEnpro Petroleum Ltd., a joint venture of GeoPetrol and Jubilant Enpro (a member of the wider Jubilant Bhartia Group), is the operator of the Kharsang Field. Jubilant holds a 25% interest in the block through its subsidiary, Jubilant Energy (Kharsang) Pvt Ltd. The other members of the consortium are Oil India Ltd and GeoPetrol.

Successful Testing and Production of Seventh Development Well of Phase-III Drilling Campaign in the Oil Producing Kharsang Field Jubilant is pleased to announce that KSG#64 (KPL-B), the last well of the seven well Phase-III development drilling campaign in the oil producing Kharsang Field, Arunachal Pradesh, has been successfully tested for oil and has been put on production at an initial gross rate of 226 barrels of oil per day. The seventh development well KSG#64 (previously referred to as KPL-B) was proposed as a step-out development well in the southern part of the Kharsang Field with the primary objective of S-00 sand and the secondary objectives of M-00 and T-00 sands. The well was spudded on 31 May 2012 and successfully drilled to a target depth of 1557 meters Measured Depth ("MD") (1367 meters True Vertical Depth) and completed on 15 July 2012 as planned. The well KSG#64 was tested with the smaller capacity work-over rig which commenced on 3 August 2012. Based on the wireline log interpretation, mud log shows, and formation pressure data from the Reservoir Dynamic Tester, the consortium has identified the interval of 1483 meters to 1486 meters MD in the S-00 reservoir sand for testing. Detailed testing was carried out in this zone and presently the well is producing at a rate of around 226 bopd on self-flow mode. In addition to the currently producing S-00 reservoir sand, one potential hydrocarbon bearing zone in the bottommost T-00 sand in the interval 1529 meters to 1532 meters MD has also been tested and produced gas with FTHP 425 psi and CHP 853 psi through 7mm choke.

http://www.investegate.co.uk/Article.aspx?id=201208200700063338K

Commenting on the collaboration, Dr. Ian Pike, COO at Proteome, said "We are delighted that CHDI has selected PS Biomarker Services™ to deliver potential proteomic markers that could help elucidate mechanisms of Huntington's disease pathology. The link between the Huntington's disease genotype and disease phenotype remains poorly understood and we will apply our Tandem Mass Tag workflows to provide high density protein expression maps in cell lines carrying different CAG-repeat lengths. Proteome Sciences has previously performed studies to identify biomarkers of HD progression in blood, and several of these are being independently evaluated as potential pharmacodynamic markers in the PADDINGTON study." Jamshid Arjomand, PhD, Director, Basic Research at CHDI, said "We are excited to implement a robust proteomic platform in support of our systems biology efforts at CHDI. Proteome Sciences' expertise in this domain will provide an additional layer of information to help us and the wider HD research community probe the pathological mechanisms involved in this devastating disorder."

Proteome Sciences to collaborate with CHDI Foundation on Huntington's disease research 20 August 2012 - London, UK. Proteome Sciences plc (Proteome) has announced that they will collaborate with CHDI Foundation, Inc. on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services™ protein profiling to CHDI's research programs. The analyses will be performed at Proteome's facility in Frankfurt am Main (Germany), which is certified according to the international quality standards of ISO 9001:2008.

http://www.investegate.co.uk/Article.aspx?id=201208200700063158K

Current trading and outlook Trading at the beginning of the second half has started positively. We plan to build on the solid progress of the first half with Harpin and Myconate and continue to implement the established strategy. In closing, I am very excited to have joined Plant Health Care. This is a high growth business with a significant pipeline of opportunities that is addressing the challenge of sustainable intensification of agriculture, to help feed the world. I expect great things from this business. As I get to know the Company better, I will be working with management to find ways to enhance growth and to deliver improved shareholder returns. I look forward to providing further updates over the coming months.

John Brady, CEO, commented: "The sector is going through a period of significant change as worldwide growth in food consumption drives the need for more efficient methods of food production. We have witnessed a 49% increase in sales of our core Harpin and Myconate technology platforms and are looking forward to developing this further in the second half."

Operational Highlights · Distribution deals agreed with ASP Chile, a subsidiary of Agrium, Inc. (a leading global fertiliser company,) and commercialisation of the agreement with Alexin (a US agricultural input distributor) · Development agreements announced with two major multinational companies: o Arysta Life Science o Makhteshim Agan Industries · Based on positive greenhouse results, six new Harpin products are currently in field trials and we are optimistic these new Harpins will present significant crop specific growth opportunities · The appointment of Dr.Christopher Richards as new Chairman strengthens industry knowledge

Results for the six months ended 30 June 2012 Plant Health Care (AIM/ CISX: PHC.L), a leading provider of naturally-derived products to the agriculture industry, announces its interim results for the six months ended 30 June 2012. Financial Highlights · Revenue flat on corresponding period in 2011 at $3.5 million o Sales of Harpin and Myconate up 49% - now represent 27% of Group revenue o Demand for Harpin understated because of Monsanto inventory overhang o Usage of Harpin, in the USA, for the 2012 crop season is estimated to exceed the total for 2011 by more than 180% · Gross margin remains strong and steady at 51% · Operating costs reduced by 4% on corresponding period in 2011 · Expenditure on R&D maintained · Cash and cash equivalents at 30 June 2012 of $10.2 million

http://www.investegate.co.uk/Article.aspx?id=201208200700063150K

Good figures and returns but the market is likely to focus on the 'weakness' comments for the months ahead.